[
{
"nct_id": "NCT06008379",
"title": "A Phase 1/2 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in Subjects With Advanced Solid Tumors",
"drugs": [
"7MW3711"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Unknown",
"start": "2023-08-28",
"start_year": 2023,
"sponsor": "Mabwell (Shanghai) Bioscience Co., Ltd.",
"gosset_sponsors": [
"Mabwell"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 164,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06008366",
"title": "A Phase \u2160/\u2161 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in Subjects With Advanced Solid Tumors",
"drugs": [
"7MW3711"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Unknown",
"start": "2023-09-05",
"start_year": 2023,
"sponsor": "Mabwell (Shanghai) Bioscience Co., Ltd.",
"gosset_sponsors": [
"Mabwell"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 281,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07466160",
"title": "A Multi-center, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of 7MW3711 in Combination With JS207 With or Without Chemotheray in Patients With Advanced Solid Tumors",
"drugs": [
"7MW3711"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-02-11",
"start_year": 2026,
"sponsor": "Mabwell (Shanghai) Bioscience Co., Ltd.",
"gosset_sponsors": [
"Mabwell"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 280,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT06934889",
"title": "Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor",
"drugs": [
"ABBV-637",
"mirzotamab clezutoclax"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-04-07",
"start_year": 2025,
"sponsor": "Memorial Sloan Kettering Cancer Center",
"gosset_sponsors": [
"Memorial Sloan Kettering Cancer Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"glioblastoma (GBM)",
"Gliosarcoma (GS)"
],
"disease_groups": [
"Brain & CNS tumours",
"Sarcomas"
],
"enrollment": 60,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT07847281",
"title": "A Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK157D1 in the Treatment of Advanced Solid Tumors Conditions",
"drugs": [
"AK157D1"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2026-09-21",
"start_year": 2026,
"sponsor": "Akeso",
"gosset_sponsors": [
"Akeso, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 243,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05405621",
"title": "A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 in Patients With Advanced Solid Tumours",
"drugs": [
"BAT8009"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Unknown",
"start": "2022-08-02",
"start_year": 2022,
"sponsor": "Bio-Thera Solutions",
"gosset_sponsors": [
"Bio-Thera Solutions, Ltd."
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 48,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06422520",
"title": "A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors",
"drugs": [
"BGB-C354"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Completed",
"start": "2024-07-08",
"start_year": 2024,
"sponsor": "BeOne Medicines",
"gosset_sponsors": [
"BeOne Medicines"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"China",
"United States"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 63,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT05914116",
"title": "A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors",
"drugs": [
"db-1311"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2023-08-17",
"start_year": 2023,
"sponsor": "DualityBio Inc.",
"gosset_sponsors": [
"Duality Biotherapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"China",
"Taiwan",
"United States"
],
"diseases": [
"small cell lung cancer (SCLC)",
"non-small cell lung cancer (NSCLC)",
"Esophageal Squamous Cell Carcinoma (ESCC)",
"castration-resistant prostate cancer (CRPC)",
"melanoma",
"hepatocellular carcinoma (HCC)",
"Cervical Cancer (CC)",
"head and neck squamous cell carcinoma (HNSCC)",
"ovarian cancer",
"prostate cancer (PCa)"
],
"disease_groups": [
"Small cell lung cancer",
"Non-small cell lung cancer",
"Oesophageal cancer",
"Prostate cancer",
"Melanoma",
"Liver cancer",
"Head & neck cancer",
"Ovarian cancer"
],
"enrollment": 862,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06892548",
"title": "A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer",
"drugs": [
"db-1311",
"pumitamig"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-05-02",
"start_year": 2025,
"sponsor": "BioNTech SE",
"gosset_sponsors": [
"BioNTech SE"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"China",
"France",
"Italy",
"Poland",
"Spain",
"Taiwan",
"Turkey (T\u00fcrkiye)",
"United Kingdom",
"United States"
],
"diseases": [
"non-small cell lung cancer (NSCLC)",
"small cell lung cancer (SCLC)"
],
"disease_groups": [
"Non-small cell lung cancer",
"Small cell lung cancer"
],
"enrollment": 594,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT06554795",
"title": "A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants With Advanced/Metastatic Solid Tumors",
"drugs": [
"DB-1419"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2024-09-03",
"start_year": 2024,
"sponsor": "DualityBio Inc.",
"gosset_sponsors": [
"Duality Biotherapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"China",
"United States"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 360,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT02192567",
"title": "Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients With Advanced Solid Malignant Tumors",
"drugs": [
"DS-5573a"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Terminated",
"start": "2014-09",
"start_year": 2014,
"sponsor": "Daiichi Sankyo Co., Ltd.",
"gosset_sponsors": [
"Daiichi Sankyo Co., Ltd."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Japan"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 19,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07177937",
"title": "An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients With Advanced Solid Tumors.",
"drugs": [
"dxc014"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-03-03",
"start_year": 2026,
"sponsor": "Hangzhou DAC Biotechnology Co., Ltd.",
"gosset_sponsors": [
"Hangzhou DAC Biotech"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"small cell lung cancer (SCLC)",
"melanoma",
"prostate cancer (PCa)",
"solid tumor"
],
"disease_groups": [
"Small cell lung cancer",
"Melanoma",
"Prostate cancer",
"Solid tumours (basket)"
],
"enrollment": 150,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07252414",
"title": "A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants With Advanced Solid Tumors",
"drugs": [
"GenSci143"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-12-20",
"start_year": 2025,
"sponsor": "Changchun GeneScience Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Changchun GeneScience Pharmaceutical Co., Ltd."
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)",
"metastatic castration-resistant prostate cancer (mCRPC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Prostate cancer"
],
"enrollment": 180,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06780137",
"title": "A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer",
"drugs": [
"gocatamig",
"ifinatamab deruxtecan"
],
"modality": "ADC",
"modality_detail": "Immunotherapy",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-02-27",
"start_year": 2025,
"sponsor": "Merck Sharp & Dohme LLC",
"gosset_sponsors": [
"Merck & Co."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Argentina",
"Australia",
"Chile",
"China",
"Israel",
"Japan",
"South Korea",
"Spain",
"Taiwan",
"Turkey (T\u00fcrkiye)",
"United Kingdom",
"United States"
],
"diseases": [
"small cell lung cancer (SCLC)"
],
"disease_groups": [
"Small cell lung cancer"
],
"enrollment": 327,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07227597",
"title": "A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer",
"drugs": [
"gocatamig",
"ifinatamab deruxtecan"
],
"modality": "ADC",
"modality_detail": "Immunotherapy",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-01-29",
"start_year": 2026,
"sponsor": "Merck Sharp & Dohme LLC",
"gosset_sponsors": [
"Merck & Co."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Argentina",
"Chile",
"China",
"Germany",
"Greece",
"Israel",
"Italy",
"Poland",
"South Korea",
"Spain",
"Thailand",
"United States"
],
"diseases": [
"small cell lung cancer (SCLC)"
],
"disease_groups": [
"Small cell lung cancer"
],
"enrollment": 170,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07274085",
"title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics, and Preliminary Antitumor Efficacy of HDM2017 in Participants With Advanced Malignant Solid Tumors",
"drugs": [
"HDM2017"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-11-18",
"start_year": 2025,
"sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Huadong Medicine"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 96,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07621159",
"title": "A Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy and Safety of HDM2017 in Combination With Standard of Care in Participants With Advanced Colorectal Cancer",
"drugs": [
"HDM2017"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Not yet recruiting",
"start": "2026-07-15",
"start_year": 2026,
"sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Huadong Medicine"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"colorectal cancer (CRC)"
],
"disease_groups": [
"Colorectal cancer"
],
"enrollment": 120,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07805551",
"title": "A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HDM2017 Combination Therapy in Participants With Advanced Colorectal Cancer",
"drugs": [
"HDM2017"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-08-18",
"start_year": 2026,
"sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Huadong Medicine"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"colorectal cancer (CRC)"
],
"disease_groups": [
"Colorectal cancer"
],
"enrollment": 220,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT05991349",
"title": "A Phase 1/2 Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors",
"drugs": [
"IBI-129"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Completed",
"start": "2024-03-12",
"start_year": 2024,
"sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
"gosset_sponsors": [
"Innovent Biologics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 36,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06349408",
"title": "A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors",
"drugs": [
"IBI3001"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-01-10",
"start_year": 2025,
"sponsor": "Fortvita Biologics (USA)Inc.",
"gosset_sponsors": [
"Fortvita Biologics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"China",
"United States"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 250,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07136558",
"title": "An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients With Advanced Solid Tumors",
"drugs": [
"ICP-B794"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2025-08",
"start_year": 2025,
"sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
"gosset_sponsors": [
"InnoCare Pharma"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 410,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07503808",
"title": "An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors",
"drugs": [
"IDE034"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-02-24",
"start_year": 2026,
"sponsor": "IDEAYA Biosciences",
"gosset_sponsors": [
"IDEAYA Biosciences"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"Esophageal Squamous Cell Carcinoma (ESCC)",
"High-Grade Serous Ovarian Carcinoma (HGSOC)",
"head and neck squamous cell carcinoma (HNSCC)",
"colorectal cancer (CRC)",
"castration-resistant prostate cancer (CRPC)",
"non-small cell lung cancer (NSCLC)",
"endometrial cancer (EC)",
"triple-negative breast cancer (TNBC)"
],
"disease_groups": [
"Oesophageal cancer",
"Ovarian cancer",
"Head & neck cancer",
"Colorectal cancer",
"Prostate cancer",
"Non-small cell lung cancer",
"Breast cancer"
],
"enrollment": 150,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT04145622",
"title": "Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)",
"drugs": [
"ifinatamab deruxtecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2019-11-03",
"start_year": 2019,
"sponsor": "Daiichi Sankyo",
"gosset_sponsors": [
"Daiichi Sankyo Co., Ltd."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Japan",
"United States"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 250,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06330064",
"title": "A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)",
"drugs": [
"ifinatamab deruxtecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2024-04-10",
"start_year": 2024,
"sponsor": "Daiichi Sankyo",
"gosset_sponsors": [
"Daiichi Sankyo Co., Ltd."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Argentina",
"Australia",
"Belgium",
"Brazil",
"Chile",
"France",
"Germany",
"Ireland",
"Italy",
"Japan",
"Mexico",
"Netherlands",
"Poland",
"Portugal",
"Spain",
"Taiwan",
"Turkey (T\u00fcrkiye)",
"United States"
],
"diseases": [
"solid tumor",
"endometrial cancer (EC)",
"head and neck squamous cell carcinoma (HNSCC)",
"pancreatic ductal adenocarcinoma (PDAC)",
"colorectal cancer (CRC)",
"hepatocellular carcinoma (HCC)",
"gastric cancer (GC)",
"urothelial carcinoma (UC)",
"ovarian cancer",
"Cervical Cancer (CC)",
"biliary tract cancer (BTC)",
"breast cancer",
"melanoma",
"neuroendocrine carcinoma (NEC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Head & neck cancer",
"Pancreatic cancer",
"Colorectal cancer",
"Liver cancer",
"Gastric / GEJ cancer",
"Ovarian cancer",
"Breast cancer",
"Melanoma"
],
"enrollment": 680,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06362252",
"title": "A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)",
"drugs": [
"ifinatamab deruxtecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2024-07-22",
"start_year": 2024,
"sponsor": "Daiichi Sankyo",
"gosset_sponsors": [
"Daiichi Sankyo Co., Ltd."
],
"sponsor_class": "INDUSTRY",
"countries": [
"France",
"Japan",
"Spain",
"United States"
],
"diseases": [
"small cell lung cancer (SCLC)"
],
"disease_groups": [
"Small cell lung cancer"
],
"enrollment": 123,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT06863272",
"title": "MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)",
"drugs": [
"ifinatamab deruxtecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-07-03",
"start_year": 2025,
"sponsor": "Merck Sharp & Dohme LLC",
"gosset_sponsors": [
"Merck & Co."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Argentina",
"Australia",
"Brazil",
"Canada",
"Chile",
"France",
"Germany",
"Ireland",
"Israel",
"Italy",
"Netherlands",
"New Zealand",
"Poland",
"South Korea",
"Spain",
"Taiwan",
"Turkey (T\u00fcrkiye)",
"United Kingdom",
"United States"
],
"diseases": [
"castration-resistant prostate cancer (CRPC)"
],
"disease_groups": [
"Prostate cancer"
],
"enrollment": 360,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT06780111",
"title": "A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E",
"drugs": [
"ifinatamab deruxtecan",
"sacituzumab tirumotecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-07-30",
"start_year": 2025,
"sponsor": "Merck Sharp & Dohme LLC",
"gosset_sponsors": [
"Merck & Co."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Brazil",
"Chile",
"China",
"Czechia",
"France",
"Germany",
"Italy",
"Japan",
"Norway",
"Singapore",
"South Korea",
"Switzerland",
"Taiwan",
"Thailand",
"Turkey (T\u00fcrkiye)",
"United States"
],
"diseases": [
"Esophageal Squamous Cell Carcinoma (ESCC)"
],
"disease_groups": [
"Oesophageal cancer"
],
"enrollment": 298,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07405151",
"title": "A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F",
"drugs": [
"ifinatamab deruxtecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-03-27",
"start_year": 2026,
"sponsor": "Merck Sharp & Dohme LLC",
"gosset_sponsors": [
"Merck & Co."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Brazil",
"Chile",
"China",
"Czechia",
"Japan",
"Norway",
"South Korea",
"Switzerland",
"Taiwan",
"Thailand",
"United States"
],
"diseases": [
"Esophageal Squamous Cell Carcinoma (ESCC)"
],
"disease_groups": [
"Oesophageal cancer"
],
"enrollment": 60,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07630974",
"title": "LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors",
"drugs": [
"ifinatamab deruxtecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-07-06",
"start_year": 2026,
"sponsor": "Merck Sharp & Dohme LLC",
"gosset_sponsors": [
"Merck & Co."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"Belgium",
"Denmark",
"France",
"Israel",
"Netherlands",
"South Korea",
"Spain",
"Sweden",
"United States"
],
"diseases": [
"solid tumor",
"osteosarcoma (OS)",
"neuroblastoma",
"rhabdomyosarcoma (RMS)",
"Wilms' tumor"
],
"disease_groups": [
"Solid tumours (basket)",
"Sarcomas",
"Neuroblastoma"
],
"enrollment": 134,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06426680",
"title": "Phase I/II Study of the ILB-3101 in Patients with Advanced Solid Tumors",
"drugs": [
"ILB-3101"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-10-30",
"start_year": 2024,
"sponsor": "Innolake Biopharm",
"gosset_sponsors": [
"Guangzhou Women and Children\u2019s Medical Center"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 240,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07423117",
"title": "A Phase 1a/b, Open-label, Multicenter, First-in-human, Dose Escalation/Expansion Study With Multiple Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Efficacy of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy",
"drugs": [
"ITC-6146RO"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2026-02-06",
"start_year": 2026,
"sponsor": "IntoCell, Inc",
"gosset_sponsors": [
"IntoCell"
],
"sponsor_class": "INDUSTRY",
"countries": [],
"diseases": [
"metastatic castration-resistant prostate cancer (mCRPC)",
"non-small cell lung cancer (NSCLC)",
"triple-negative breast cancer (TNBC)",
"solid tumor"
],
"disease_groups": [
"Prostate cancer",
"Non-small cell lung cancer",
"Breast cancer",
"Solid tumours (basket)"
],
"enrollment": 102,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07307053",
"title": "An Open-Label, Single-Arm, Phase I/II Platform Trial of Innovative Therapies and Technologies Primarily in Rare Tumors in China (PLATFORM2) in Patients With Advanced Solid Tumors",
"drugs": [
"izalontamab brengitecan",
"vesicular stomatitis virus",
"CVL006",
"IDOV-Safe",
"YL201",
"KXV01 TCR Lentinvivo",
"MT027 CAR-T cells",
"QH101",
"metabolically armed tumor-infiltrating lymphocytes",
"TAEST1901",
"TC-N201",
"NK510",
"CE120",
"GV20-0251",
"recombinant L-IFN adenovirus",
"LYC001",
"BMD006",
"CREPT-618",
"PRG2505",
"IBI363"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Not yet recruiting",
"start": "2026-01-01",
"start_year": 2026,
"sponsor": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences",
"gosset_sponsors": [
"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
],
"sponsor_class": "OTHER",
"countries": [],
"diseases": [],
"disease_groups": [],
"enrollment": 600,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06242470",
"title": "A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors",
"drugs": [
"MGC026"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-03-06",
"start_year": 2024,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"United Kingdom",
"United States"
],
"diseases": [
"solid tumor (advanced stage)",
"head and neck squamous cell carcinoma (HNSCC)",
"non-small cell lung cancer (NSCLC)",
"small cell lung cancer (SCLC)",
"bladder cancer",
"sarcoma",
"endometrial cancer (EC)",
"melanoma",
"castration-resistant prostate cancer (CRPC)",
"Cervical Cancer (CC)",
"colorectal cancer (CRC)",
"gastric cancer (GC)",
"gastroesophageal junction cancer",
"pancreatic cancer (PC)",
"clear cell renal cell carcinoma (ccRCC)",
"hepatocellular carcinoma (HCC)",
"ovarian cancer",
"breast cancer",
"Esophageal Squamous Cell Carcinoma (ESCC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Head & neck cancer",
"Non-small cell lung cancer",
"Small cell lung cancer",
"Sarcomas",
"Melanoma",
"Prostate cancer",
"Colorectal cancer",
"Gastric / GEJ cancer",
"Oesophageal cancer",
"Pancreatic cancer",
"Liver cancer",
"Ovarian cancer",
"Breast cancer"
],
"enrollment": 250,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05652855",
"title": "Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors",
"drugs": [
"MHB088C"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Unknown",
"start": "2023-01-23",
"start_year": 2023,
"sponsor": "Minghui Pharmaceutical Pty Ltd",
"gosset_sponsors": [
"Minghui Pharmaceutical, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia"
],
"diseases": [
"solid tumor",
"metastatic solid tumor",
"non-small cell lung cancer (NSCLC)",
"small cell lung cancer (SCLC)",
"Esophageal Squamous Cell Carcinoma (ESCC)",
"castration-resistant prostate cancer (CRPC)",
"melanoma",
"colorectal cancer (CRC)",
"pancreatic ductal adenocarcinoma (PDAC)",
"head and neck squamous cell carcinoma (HNSCC)",
"hepatocellular carcinoma (HCC)",
"ovarian cancer",
"endometrial cancer (EC)",
"thyroid cancer",
"sarcoma"
],
"disease_groups": [
"Solid tumours (basket)",
"Non-small cell lung cancer",
"Small cell lung cancer",
"Oesophageal cancer",
"Prostate cancer",
"Melanoma",
"Colorectal cancer",
"Pancreatic cancer",
"Head & neck cancer",
"Liver cancer",
"Ovarian cancer",
"Sarcomas"
],
"enrollment": 48,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07102004",
"title": "A Phase I/II Study of MHB088C for Patients With Advanced Malignant Solid Tumors",
"drugs": [
"MHB088C"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2023-06-20",
"start_year": 2023,
"sponsor": "Qilu Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Qilu Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)",
"small cell lung cancer (SCLC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Small cell lung cancer"
],
"enrollment": 515,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07126665",
"title": "An Open-label Phase I/II Clinical Study of MHB088C for Injection Combined With MHB039A for Injection in Patients With Advanced Malignant Solid Tumors",
"drugs": [
"MHB088C",
"MHB039A"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-09-18",
"start_year": 2025,
"sponsor": "Minghui Pharmaceutical (Hangzhou) Ltd",
"gosset_sponsors": [
"Minghui Pharmaceutical, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"advanced malignant solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 116,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07256782",
"title": "A Phase Ib/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of QLC5508 in Combination With Other Anti-tumor Agents in Patients With Advanced Solid Tumors",
"drugs": [
"MHB088C"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-10-24",
"start_year": 2025,
"sponsor": "Qilu Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Qilu Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 444,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07198633",
"title": "An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer",
"drugs": [
"MHB088C",
"QLH12016"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-11-05",
"start_year": 2025,
"sponsor": "Qilu Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Qilu Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"prostate cancer (PCa)"
],
"disease_groups": [
"Prostate cancer"
],
"enrollment": 212,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07620041",
"title": "A Phase 1 Study to Evaluate the C-QTc Interval of QLC5508, Compare the Pharmacokinetics of Two Different Formulations, and Assess Drug-Drug Interaction Potential in Participants With Advanced Solid Tumors",
"drugs": [
"MHB088C"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-06-09",
"start_year": 2026,
"sponsor": "Qilu Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Qilu Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 48,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT03595059",
"title": "A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors",
"drugs": [
"mirzotamab clezutoclax"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Completed",
"start": "2018-07-13",
"start_year": 2018,
"sponsor": "AbbVie",
"gosset_sponsors": [
"AbbVie Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"Canada",
"Israel",
"Japan",
"Netherlands",
"Puerto Rico",
"South Korea",
"Spain",
"Taiwan",
"United States"
],
"diseases": [
"small cell lung cancer (SCLC)",
"non-small cell lung cancer (NSCLC)",
"breast cancer"
],
"disease_groups": [
"Small cell lung cancer",
"Non-small cell lung cancer",
"Breast cancer"
],
"enrollment": 168,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07807241",
"title": "A Phase 1a/b, Open-label, Dose-escalation and Dose-expansion, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of MX006 in Patients With Selected Advanced Solid Tumor Types Known to Express B7-H3",
"drugs": [
"MX006"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-07-20",
"start_year": 2026,
"sponsor": "Myricx Pharma Limited",
"gosset_sponsors": [
"Myricx Bio"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 120,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07612176",
"title": "A Phase 1 Dose Escalation and Expansion Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific Antibody-Drug Conjugate, in Participants With Select, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors",
"drugs": [
"NEOK001"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-04-21",
"start_year": 2026,
"sponsor": "NEOK Bio, Inc.",
"gosset_sponsors": [
"NEOK Bio"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 155,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07537881",
"title": "A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC288 for Injection in the Treatment of Locally Advanced Unresectable or Metastatic Malignant Solid Tumor.",
"drugs": [
"RC288"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-04-27",
"start_year": 2026,
"sponsor": "RemeGen Co., Ltd.",
"gosset_sponsors": [
"RemeGen"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 326,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT05276609",
"title": "ARTEMIS-001: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Intravenous Administration of HS-20093 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Unknown",
"start": "2021-11-28",
"start_year": 2021,
"sponsor": "Shanghai Hansoh Biomedical Co., Ltd",
"gosset_sponsors": [
"Hansoh Pharmaceutical Group"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)",
"non-small cell lung cancer (NSCLC)",
"small cell lung cancer (SCLC)",
"metastatic castration-resistant prostate cancer (mCRPC)",
"esophageal carcinoma",
"head and neck squamous cell carcinoma (HNSCC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Non-small cell lung cancer",
"Small cell lung cancer",
"Prostate cancer",
"Oesophageal cancer",
"Head & neck cancer"
],
"enrollment": 177,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06332170",
"title": "ARTEMIS-101: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-04-26",
"start_year": 2024,
"sponsor": "Hansoh BioMedical R&D Company",
"gosset_sponsors": [
"Hansoh Pharmaceutical Group"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 610,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT06551142",
"title": "A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-09-30",
"start_year": 2024,
"sponsor": "GlaxoSmithKline",
"gosset_sponsors": [
"GSK"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Argentina",
"Canada",
"France",
"Hong Kong",
"Israel",
"Italy",
"Japan",
"Panama",
"South Korea",
"Spain",
"Taiwan",
"United Kingdom",
"United States"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 845,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06825624",
"title": "ARTEMIS-102: a Phase Ib Study of HS-20093 Combination Therapy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Metastatic Colorectal Cancer",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-10-03",
"start_year": 2024,
"sponsor": "Hansoh BioMedical R&D Company",
"gosset_sponsors": [
"Hansoh Pharmaceutical Group"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"colorectal cancer (metastatic) (mCRC)"
],
"disease_groups": [
"Colorectal cancer"
],
"enrollment": 560,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT06699576",
"title": "ARTEMIS-103: a Phase 1b, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination with Other Anti-cancer Agents in Patients with Bone and Soft Tissue Sarcoma.",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2024-12-20",
"start_year": 2024,
"sponsor": "Hansoh BioMedical R&D Company",
"gosset_sponsors": [
"Hansoh Pharmaceutical Group"
],
"sponsor_class": "INDUSTRY",
"countries": [],
"diseases": [
"osteosarcoma (OS)",
"soft tissue sarcoma (STS)"
],
"disease_groups": [
"Sarcomas"
],
"enrollment": 448,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT06885034",
"title": "A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-06-11",
"start_year": 2025,
"sponsor": "GlaxoSmithKline",
"gosset_sponsors": [
"GSK"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"Belgium",
"Brazil",
"Canada",
"Finland",
"France",
"Germany",
"Italy",
"Japan",
"Mexico",
"Netherlands",
"Norway",
"Panama",
"Poland",
"South Korea",
"Spain",
"Sweden",
"United Kingdom",
"United States"
],
"diseases": [
"colorectal cancer (CRC)",
"pancreatic cancer (PC)"
],
"disease_groups": [
"Colorectal cancer",
"Pancreatic cancer"
],
"enrollment": 451,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07063407",
"title": "A Phase I Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2025-07-31",
"start_year": 2025,
"sponsor": "Shanghai Hansoh Biomedical Co., Ltd",
"gosset_sponsors": [
"Hansoh Pharmaceutical Group"
],
"sponsor_class": "INDUSTRY",
"countries": [],
"diseases": [
"small cell lung cancer (SCLC)"
],
"disease_groups": [
"Small cell lung cancer"
],
"enrollment": 50,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT07115446",
"title": "A Phase Ib Study to Explore the Safety, Tolerability, and Pharmacokinetics of HS-20093 Combination With HRS-5041 in Patients With Advanced Prostate Cancer",
"drugs": [
"risvutatug rezetecan",
"HRS-5041"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-08-19",
"start_year": 2025,
"sponsor": "Hansoh BioMedical R&D Company",
"gosset_sponsors": [
"Hansoh Pharmaceutical Group"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"prostate cancer (PCa)"
],
"disease_groups": [
"Prostate cancer"
],
"enrollment": 63,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT07186452",
"title": "A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors Who Have Failed Adequate Standard Treatments or Are Intolerant to Standard Therapies",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-09-23",
"start_year": 2025,
"sponsor": "Hansoh BioMedical R&D Company",
"gosset_sponsors": [
"Hansoh Pharmaceutical Group"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 18,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT07277270",
"title": "A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-12-03",
"start_year": 2025,
"sponsor": "GlaxoSmithKline",
"gosset_sponsors": [
"GSK"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"Canada",
"South Korea",
"Spain",
"United Kingdom",
"United States"
],
"diseases": [
"colorectal cancer (CRC)",
"prostate cancer (PCa)"
],
"disease_groups": [
"Colorectal cancer",
"Prostate cancer"
],
"enrollment": 83,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT07462923",
"title": "A Phase Ib Clinical Study on the Efficacy, Safety, Tolerability, and Pharmacokinetics of HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-01-29",
"start_year": 2026,
"sponsor": "Hansoh BioMedical R&D Company",
"gosset_sponsors": [
"Hansoh Pharmaceutical Group"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"gastric adenocarcinoma",
"gastroesophageal junction adenocarcinoma"
],
"disease_groups": [
"Gastric / GEJ cancer",
"Oesophageal cancer"
],
"enrollment": 40,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07268053",
"title": "A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Early Phase 1",
"status": "Recruiting",
"start": "2026-02-11",
"start_year": 2026,
"sponsor": "Nader Sanai",
"gosset_sponsors": [
"Ivy Brain Tumor Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"glioblastoma (GBM)",
"brain metastases"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 15,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07602777",
"title": "Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-06-22",
"start_year": 2026,
"sponsor": "GlaxoSmithKline",
"gosset_sponsors": [
"GSK"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Canada",
"France",
"Israel",
"Japan",
"United Kingdom",
"United States"
],
"diseases": [
"osteosarcoma (OS)",
"soft tissue sarcoma (STS)"
],
"disease_groups": [
"Sarcomas"
],
"enrollment": 64,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07602855",
"title": "A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors",
"drugs": [
"risvutatug rezetecan"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-09-09",
"start_year": 2026,
"sponsor": "GlaxoSmithKline",
"gosset_sponsors": [
"GSK"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Japan",
"United States"
],
"diseases": [
"lung cancer"
],
"disease_groups": [
"Lung cancer (unspecified)"
],
"enrollment": 184,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT06736327",
"title": "A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 for Injection in Subjects With Advanced Solid Tumors",
"drugs": [
"SKB500"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-12-13",
"start_year": 2024,
"sponsor": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Kelun-Biotech"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 180,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07415863",
"title": "Phase I/II Dose-Escalation, PK Expansion and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors",
"drugs": [
"SYS6043"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2024-12-30",
"start_year": 2024,
"sponsor": "CSPC Megalith Biopharmaceutical Co.,Ltd.",
"gosset_sponsors": [
"CSPC Megalith Biopharmaceutical Co., Ltd."
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 820,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07424547",
"title": "Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors",
"drugs": [
"SYS6043"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-03-03",
"start_year": 2026,
"sponsor": "Conjupro Biotherapeutics, Inc.",
"gosset_sponsors": [
"Conjupro Biotherapeutics, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"solid tumor",
"small cell lung cancer (SCLC)",
"breast cancer",
"prostate cancer (PCa)",
"ovarian cancer"
],
"disease_groups": [
"Solid tumours (basket)",
"Small cell lung cancer",
"Breast cancer",
"Prostate cancer",
"Ovarian cancer"
],
"enrollment": 386,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07833735",
"title": "An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SYS6043 With or Without Bevacizumab, With or Without Chemotherapy in Participants With Advanced Solid Tumors",
"drugs": [
"SYS6043"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Not yet recruiting",
"start": "2026-10-15",
"start_year": 2026,
"sponsor": "CSPC Megalith Biopharmaceutical Co.,Ltd.",
"gosset_sponsors": [
"CSPC Megalith Biopharmaceutical Co., Ltd."
],
"sponsor_class": "INDUSTRY",
"countries": [],
"diseases": [
"solid tumor",
"ovarian cancer",
"fallopian tube cancer (PFTC)",
"primary peritoneal cancer (PPC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Ovarian cancer"
],
"enrollment": 400,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT06898957",
"title": "A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer",
"drugs": [
"tarlatamab",
"YL201"
],
"modality": "ADC",
"modality_detail": "BiTE",
"phase": "Phase 1",
"status": "Active, not recruiting",
"start": "2025-05-16",
"start_year": 2025,
"sponsor": "Amgen",
"gosset_sponsors": [
"Amgen"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Canada",
"China",
"France",
"Germany",
"Greece",
"Hungary",
"Italy",
"South Korea",
"Spain",
"United States"
],
"diseases": [
"small cell lung cancer (SCLC)"
],
"disease_groups": [
"Small cell lung cancer"
],
"enrollment": 29,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT07222969",
"title": "An Open-label, Dose-escalation and Dose-expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics, and Preliminary Efficacy of VIB305 in Patients With Advanced Solid Tumors",
"drugs": [
"VIB305"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-01-12",
"start_year": 2026,
"sponsor": "Vibrant Sciences Limited",
"gosset_sponsors": [
"Vibrant Sciences"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 146,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT04165070",
"title": "KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)",
"drugs": [
"vibostolimab",
"boserolimab",
"mk-4830",
"rolistobart",
"ifinatamab deruxtecan",
"patritumab"
],
"modality": "ADC",
"modality_detail": "mAb",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2019-12-19",
"start_year": 2019,
"sponsor": "Merck Sharp & Dohme LLC",
"gosset_sponsors": [
"Merck & Co."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Hungary",
"Israel",
"Italy",
"Poland",
"South Korea",
"Spain",
"Taiwan",
"Ukraine",
"United States"
],
"diseases": [
"non-small cell lung cancer (NSCLC)"
],
"disease_groups": [
"Non-small cell lung cancer"
],
"enrollment": 450,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT03729596",
"title": "A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors",
"drugs": [
"vobramitamab duocarmazine"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Terminated",
"start": "2018-11-21",
"start_year": 2018,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"Poland",
"Spain",
"United States"
],
"diseases": [
"solid tumor",
"metastatic castration-resistant prostate cancer (mCRPC)",
"non-small cell lung cancer (NSCLC)",
"triple-negative breast cancer (TNBC)",
"squamous cell carcinoma of the head and neck (HNSCC)",
"melanoma"
],
"disease_groups": [
"Solid tumours (basket)",
"Prostate cancer",
"Non-small cell lung cancer",
"Breast cancer",
"Head & neck cancer",
"Melanoma"
],
"enrollment": 143,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT05293496",
"title": "A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors",
"drugs": [
"vobramitamab duocarmazine"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Completed",
"start": "2022-04-19",
"start_year": 2022,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"metastatic castration-resistant prostate cancer (mCRPC)",
"melanoma",
"pancreatic cancer (PC)",
"hepatocellular carcinoma (HCC)",
"ovarian cancer",
"renal cell carcinoma (RCC)"
],
"disease_groups": [
"Prostate cancer",
"Melanoma",
"Pancreatic cancer",
"Liver cancer",
"Ovarian cancer"
],
"enrollment": 31,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT05434234",
"title": "A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors",
"drugs": [
"YL201"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2022-05-25",
"start_year": 2022,
"sponsor": "MediLink Therapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"MediLink Therapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Canada",
"China",
"France",
"Poland",
"Spain",
"United States"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 312,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06057922",
"title": "A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Selected Advanced Solid Tumors",
"drugs": [
"YL201"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Active, not recruiting",
"start": "2023-09-22",
"start_year": 2023,
"sponsor": "MediLink Therapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"MediLink Therapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)",
"non-small cell lung cancer (NSCLC)",
"small cell lung cancer (SCLC)",
"nasopharyngeal carcinoma (NPC)",
"Esophageal Squamous Cell Carcinoma (ESCC)",
"metastatic castration-resistant prostate cancer (mCRPC)",
"head and neck squamous cell carcinoma (HNSCC)",
"sarcoma",
"pancreatic ductal adenocarcinoma (PDAC)",
"hepatocellular carcinoma (HCC)",
"biliary tract cancer (BTC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Non-small cell lung cancer",
"Small cell lung cancer",
"Head & neck cancer",
"Oesophageal cancer",
"Prostate cancer",
"Sarcomas",
"Pancreatic cancer",
"Liver cancer"
],
"enrollment": 990,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06394414",
"title": "A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Serplulimab With or Without Platinum-based Chemotherapy in Selected Subjects With Advanced Solid Tumors",
"drugs": [
"YL201"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1",
"status": "Active, not recruiting",
"start": "2024-04-17",
"start_year": 2024,
"sponsor": "MediLink Therapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"MediLink Therapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 187,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT07208773",
"title": "A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors",
"drugs": [
"YL201"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-10-29",
"start_year": 2025,
"sponsor": "MediLink Therapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"MediLink Therapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor",
"non-small cell lung cancer (NSCLC)",
"small cell lung cancer (SCLC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Non-small cell lung cancer",
"Small cell lung cancer"
],
"enrollment": 260,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07258979",
"title": "A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 Combined With Toripalimab, With or Without Cisplatin, in Subjects With Recurrent or Metastatic Nasopharyngeal Carcinoma.",
"drugs": [
"YL201"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2025-11-05",
"start_year": 2025,
"sponsor": "MediLink Therapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"MediLink Therapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"nasopharyngeal carcinoma (NPC)"
],
"disease_groups": [
"Head & neck cancer"
],
"enrollment": 202,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07407933",
"title": "A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors",
"drugs": [
"YL201"
],
"modality": "ADC",
"modality_detail": "ADC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-03-31",
"start_year": 2026,
"sponsor": "MediLink Therapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"MediLink Therapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Belgium",
"France",
"Hungary",
"Italy",
"Poland",
"Romania",
"Spain",
"United Kingdom",
"United States"
],
"diseases": [
"Small Cell Lung Cancer (SCLC)"
],
"disease_groups": [
"Small cell lung cancer"
],
"enrollment": 118,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT07455734",
"title": "A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors",
"drugs": [
"BNT3214"
],
"modality": "Antibody & other",
"modality_detail": "mAb",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-03-30",
"start_year": 2026,
"sponsor": "BioNTech SE",
"gosset_sponsors": [
"BioNTech SE"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"China",
"South Korea",
"Taiwan"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 533,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07541534",
"title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX316 (B7-H3 Targeting Sialidase Fc Fusion Protein) in Participants With Advanced/Metastatic Solid Tumors",
"drugs": [
"E-688"
],
"modality": "Antibody & other",
"modality_detail": "RFP",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-05-22",
"start_year": 2026,
"sponsor": "Shanghai Henlius Biotech",
"gosset_sponsors": [
"Henlius"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor",
"ovarian cancer",
"primary peritoneal cancer (PPC)",
"fallopian tube cancer (PFTC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Ovarian cancer"
],
"enrollment": 41,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT01391143",
"title": "A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer",
"drugs": [
"enoblituzumab"
],
"modality": "Antibody & other",
"modality_detail": "mAb",
"phase": "Phase 1",
"status": "Completed",
"start": "2011-07",
"start_year": 2011,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"prostate cancer (PCa)",
"melanoma",
"renal cell carcinoma (RCC)",
"triple-negative breast cancer (TNBC)",
"head and neck cancer (HNC)",
"bladder cancer",
"non-small cell lung cancer (NSCLC)"
],
"disease_groups": [
"Prostate cancer",
"Melanoma",
"Breast cancer",
"Head & neck cancer",
"Non-small cell lung cancer"
],
"enrollment": 179,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT01918930",
"title": "A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)",
"drugs": [
"enoblituzumab"
],
"modality": "Antibody & other",
"modality_detail": "mAb",
"phase": "Phase 1",
"status": "Terminated",
"start": "2013-07",
"start_year": 2013,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"melanoma"
],
"disease_groups": [
"Melanoma"
],
"enrollment": 6,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT02381314",
"title": "A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers",
"drugs": [
"enoblituzumab"
],
"modality": "Antibody & other",
"modality_detail": "mAb",
"phase": "Phase 1",
"status": "Completed",
"start": "2015-03-26",
"start_year": 2015,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"melanoma",
"non-small cell lung cancer (NSCLC)",
"squamous cell carcinoma of the head and neck (HNSCC)",
"mesothelioma",
"urothelial carcinoma (UC)",
"clear cell renal cell carcinoma (ccRCC)",
"ovarian cancer",
"thyroid cancer",
"triple-negative breast cancer (TNBC)",
"pancreatic cancer (PC)",
"colon cancer",
"soft tissue sarcoma (STS)",
"prostate cancer (PCa)"
],
"disease_groups": [
"Melanoma",
"Non-small cell lung cancer",
"Head & neck cancer",
"Colorectal cancer",
"Ovarian cancer",
"Breast cancer",
"Pancreatic cancer",
"Sarcomas",
"Prostate cancer"
],
"enrollment": 24,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT02475213",
"title": "A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers",
"drugs": [
"enoblituzumab"
],
"modality": "Antibody & other",
"modality_detail": "mAb",
"phase": "Phase 1",
"status": "Completed",
"start": "2015-07",
"start_year": 2015,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"melanoma",
"head and neck squamous cell carcinoma (HNSCC)",
"non-small cell lung cancer (NSCLC)",
"urothelial carcinoma (UC)"
],
"disease_groups": [
"Melanoma",
"Head & neck cancer",
"Non-small cell lung cancer"
],
"enrollment": 146,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT02982941",
"title": "A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients With B7-H3-Expressing Relapsed or Refractory Solid Tumors",
"drugs": [
"enoblituzumab"
],
"modality": "Antibody & other",
"modality_detail": "mAb",
"phase": "Phase 1",
"status": "Completed",
"start": "2016-12",
"start_year": 2016,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"neuroblastoma",
"rhabdomyosarcoma (RMS)",
"osteosarcoma (OS)",
"Ewing sarcoma",
"Wilms' tumor",
"desmoplastic small round cell tumor (DSRCT)",
"solid tumor"
],
"disease_groups": [
"Neuroblastoma",
"Sarcomas",
"Solid tumours (basket)"
],
"enrollment": 25,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05991583",
"title": "A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBB0979 in Patients With Locally Advanced or Metastatic Solid Tumors",
"drugs": [
"IBB0979"
],
"modality": "Antibody & other",
"modality_detail": "IC",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2023-07-03",
"start_year": 2023,
"sponsor": "SUNHO\uff08China\uff09BioPharmaceutical CO., Ltd.",
"gosset_sponsors": [
"SUNHO BioPharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 25,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07744152",
"title": "A First-in-human, Open-label, Phase I Trial to Determine the Safety and Tolerability of BI 3822971 in Patients With Unresectable Advanced or Metastatic Solid Cancers",
"drugs": [
"BI 3822971"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-09-21",
"start_year": 2026,
"sponsor": "Boehringer Ingelheim",
"gosset_sponsors": [
"Boehringer Ingelheim"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Belgium",
"China",
"Germany",
"Netherlands",
"Spain"
],
"diseases": [
"non-small cell lung cancer (NSCLC)",
"head and neck squamous cell carcinoma (HNSCC)",
"triple-negative breast cancer (TNBC)",
"Esophageal Squamous Cell Carcinoma (ESCC)",
"bladder cancer",
"vulvar cancer",
"Cervical Cancer (CC)"
],
"disease_groups": [
"Non-small cell lung cancer",
"Head & neck cancer",
"Breast cancer",
"Oesophageal cancer"
],
"enrollment": 137,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05999396",
"title": "First in Human Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer",
"drugs": [
"CC-3"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-01-12",
"start_year": 2024,
"sponsor": "German Cancer Research Center",
"gosset_sponsors": [
"German Cancer Research Center"
],
"sponsor_class": "OTHER",
"countries": [
"Germany"
],
"diseases": [
"colorectal cancer (CRC)"
],
"disease_groups": [
"Colorectal cancer"
],
"enrollment": 89,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07541573",
"title": "MT2025-14: A Phase 1a/1b Study of GTB-5550, a Camelid Nanobody TriSpecific Killer Engager (camB7-H3 TriKE\u00ae), in Select Advanced Solid Tumors That Failed Prior Therapy",
"drugs": [
"GTB-5550"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "sdAb",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-04-08",
"start_year": 2026,
"sponsor": "Masonic Cancer Center, University of Minnesota",
"gosset_sponsors": [
"Masonic Cancer Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"castration-resistant prostate cancer (CRPC)",
"breast cancer",
"pancreatic cancer (PC)",
"non-small cell lung cancer (NSCLC)",
"squamous cell carcinoma of the head and neck (HNSCC)",
"epithelial ovarian cancer (EOC)",
"bladder cancer"
],
"disease_groups": [
"Prostate cancer",
"Breast cancer",
"Pancreatic cancer",
"Non-small cell lung cancer",
"Head & neck cancer",
"Ovarian cancer"
],
"enrollment": 175,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05774873",
"title": "A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors",
"drugs": [
"IBI-334"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1/2",
"status": "Completed",
"start": "2023-08-09",
"start_year": 2023,
"sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
"gosset_sponsors": [
"Innovent Biologics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 28,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT02628535",
"title": "Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms",
"drugs": [
"obrindatamab"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Terminated",
"start": "2015-09",
"start_year": 2015,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"Canada",
"United States"
],
"diseases": [
"mesothelioma",
"bladder cancer",
"melanoma",
"head and neck squamous cell carcinoma (HNSCC)",
"non-small cell lung cancer (NSCLC)",
"clear cell renal cell carcinoma (ccRCC)",
"ovarian cancer",
"thyroid cancer",
"triple-negative breast cancer (TNBC)",
"pancreatic cancer (PC)",
"colon cancer",
"soft tissue sarcoma (STS)",
"prostate cancer (PCa)"
],
"disease_groups": [
"Melanoma",
"Head & neck cancer",
"Non-small cell lung cancer",
"Colorectal cancer",
"Ovarian cancer",
"Breast cancer",
"Pancreatic cancer",
"Sarcomas",
"Prostate cancer"
],
"enrollment": 67,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT03406949",
"title": "A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART\u00ae Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors",
"drugs": [
"obrindatamab"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Completed",
"start": "2018-02-27",
"start_year": 2018,
"sponsor": "MacroGenics",
"gosset_sponsors": [
"MacroGenics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"solid tumor (advanced stage)"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 25,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT07606612",
"title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B036 Bispecific Antibody Injection in Patients With Locally Advanced or Metastatic Solid Tumors",
"drugs": [
"SI-B036"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-06-11",
"start_year": 2026,
"sponsor": "Sichuan Baili Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Biokin Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 31,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07678970",
"title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B036 Bispecific Antibody Injection in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors",
"drugs": [
"SI-B036"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-07-30",
"start_year": 2026,
"sponsor": "Sichuan Baili Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Biokin Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"gastrointestinal tumor",
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 10,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07744243",
"title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B036 Bispecific Antibody Injection in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors",
"drugs": [
"SI-B036"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2026-08",
"start_year": 2026,
"sponsor": "Sichuan Baili Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Biokin Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"urological cancer (UC)",
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 30,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07753226",
"title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B036 Bispecific Antibody Injection in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors",
"drugs": [
"SI-B036"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-08-18",
"start_year": 2026,
"sponsor": "Sichuan Baili Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Biokin Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"breast cancer",
"solid tumor"
],
"disease_groups": [
"Breast cancer",
"Solid tumours (basket)"
],
"enrollment": 39,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07778862",
"title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B036 Bispecific Antibody Injection in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors",
"drugs": [
"SI-B036"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2026-09",
"start_year": 2026,
"sponsor": "Sichuan Baili Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Biokin Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 30,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07763639",
"title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B036 Bispecific Antibody Injection in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors",
"drugs": [
"SI-B036"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-09-23",
"start_year": 2026,
"sponsor": "Sichuan Baili Pharmaceutical Co., Ltd.",
"gosset_sponsors": [
"Biokin Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"Head and neck cancer (HNC)",
"solid tumor"
],
"disease_groups": [
"Head & neck cancer",
"Solid tumours (basket)"
],
"enrollment": 30,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05220098",
"title": "A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer",
"drugs": [
"TAK-280"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1/2",
"status": "Terminated",
"start": "2022-04-21",
"start_year": 2022,
"sponsor": "Takeda",
"gosset_sponsors": [
"Takeda"
],
"sponsor_class": "INDUSTRY",
"countries": [
"Australia",
"Canada",
"Spain",
"United States"
],
"diseases": [
"cancer"
],
"disease_groups": [],
"enrollment": 69,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07593092",
"title": "A Phase 1 Trial, Evaluating the Safety and Tolerability of XmAb541 in Combination With XmAb808 in Advanced Solid Tumors",
"drugs": [
"XmAb541",
"xmab808"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-06-30",
"start_year": 2026,
"sponsor": "Xencor, Inc.",
"gosset_sponsors": [
"Xencor"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"ovarian cancer"
],
"disease_groups": [
"Ovarian cancer"
],
"enrollment": 90,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT05585034",
"title": "A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb\u00ae808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors",
"drugs": [
"xmab808"
],
"modality": "Bispecific / T-cell engager",
"modality_detail": "BsAb",
"phase": "Phase 1",
"status": "Completed",
"start": "2022-12-14",
"start_year": 2022,
"sponsor": "Xencor, Inc.",
"gosset_sponsors": [
"Xencor"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"prostate cancer (PCa)",
"Epithelial Ovarian Cancer (EOC)",
"head and neck squamous cell carcinoma (HNSCC)",
"non-small cell lung cancer (NSCLC)",
"urothelial carcinoma (UC)",
"melanoma",
"clear cell renal cell carcinoma (ccRCC)",
"triple-negative breast cancer (TNBC)",
"colorectal cancer (CRC)"
],
"disease_groups": [
"Prostate cancer",
"Ovarian cancer",
"Head & neck cancer",
"Non-small cell lung cancer",
"Melanoma",
"Colorectal cancer",
"Breast cancer"
],
"enrollment": 60,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT04897321",
"title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",
"drugs": [
"3CAR"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2022-07-06",
"start_year": 2022,
"sponsor": "St. Jude Children's Research Hospital",
"gosset_sponsors": [
"St. Jude Children's Research Hospital"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 48,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07172958",
"title": "Selective Antigen Specific dT\u03b2RII-expressing T Cells and B7-H3 CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)",
"drugs": [
"3CAR"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-01-27",
"start_year": 2026,
"sponsor": "Children's National Research Institute",
"gosset_sponsors": [
"Children's National Research Institute"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"rhabdomyosarcoma (RMS)",
"Ewing sarcoma",
"neuroblastoma",
"Wilms' tumor"
],
"disease_groups": [
"Sarcomas",
"Neuroblastoma"
],
"enrollment": 18,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT04432649",
"title": "Multicenter Trial of Phase I/II Studies on CD276 (B7-H3) Positive Solid Tumors Treated With 4SCAR-276",
"drugs": [
"4SCAR-276"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Not yet recruiting",
"start": "2027-06-01",
"start_year": 2027,
"sponsor": "Shenzhen Geno-Immune Medical Institute",
"gosset_sponsors": [
"Shenzhen Geno-Immune Medical Institute"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 100,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT04430530",
"title": "4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia",
"drugs": [
"4SCAR-T"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Terminated",
"start": "2026-06-01",
"start_year": 2026,
"sponsor": "Shenzhen Geno-Immune Medical Institute",
"gosset_sponsors": [
"Shenzhen Geno-Immune Medical Institute"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"B cell acute lymphoblastic leukemia (B-ALL)"
],
"disease_groups": [
"Leukaemias"
],
"enrollment": 100,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07358260",
"title": "A Phase I, Open Label, Dose Escalation, Single Center Study of Autologous B7-H3.CD28Z.CART Cells in Children and Young Adults With Relapsed or Refractory Solid Tumors Expressing B7-H3",
"drugs": [
"B7-H3 UCAR-T"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-08-24",
"start_year": 2026,
"sponsor": "Robbie Majzner",
"gosset_sponsors": [],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"Pediatric solid tumor (PST)",
"neuroblastoma"
],
"disease_groups": [
"Solid tumours (basket)",
"Neuroblastoma"
],
"enrollment": 40,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07390539",
"title": "A Phase 1/1b Study of Autologous b7-h3 Chimeric Antigen Receptor t Cells (b7-h3.cd28z.Cart) in Children and Young Adults With Recurrent or Progressive Cns Neoplasms Expressing b7-h3 Target",
"drugs": [
"B7-H3 UCAR-T"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-09",
"start_year": 2026,
"sponsor": "Robbie Majzner",
"gosset_sponsors": [],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"central nervous system tumor",
"medulloblastoma",
"ependymoma",
"Atypical teratoid rhabdoid tumor (ATRT)",
"embryonal tumor with multilayered rosettes (ETMR)",
"pineoblastoma (PB)"
],
"disease_groups": [
"Brain & CNS tumours",
"Sarcomas"
],
"enrollment": 70,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05835687",
"title": "Loc3CAR: Locoregional Delivery of B7-H3-specific Chimeric Antigen Receptor Autologous T Cells for Pediatric Patients With Primary CNS Tumors",
"drugs": [
"b7-h3-car t cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Active, not recruiting",
"start": "2023-04-27",
"start_year": 2023,
"sponsor": "St. Jude Children's Research Hospital",
"gosset_sponsors": [
"St. Jude Children's Research Hospital"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"central nervous system tumor",
"diffuse midline glioma (DMG)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 29,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07222735",
"title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas",
"drugs": [
"b7-h3-car t cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-01-21",
"start_year": 2026,
"sponsor": "St. Jude Children's Research Hospital",
"gosset_sponsors": [
"St. Jude Children's Research Hospital"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"sarcoma"
],
"disease_groups": [
"Sarcomas"
],
"enrollment": 42,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05241392",
"title": "An Open, Single-arm, Phase 1 Study to Evaluate the Safety/Preliminary Effectiveness and Determine the Maximal Tolerated Dose of B7-H3-targeting CAR-T Cell Therapy in Treating Recurrent Glioblastomas",
"drugs": [
"B7-H3-targeting CAR-T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Active, not recruiting",
"start": "2022-01-27",
"start_year": 2022,
"sponsor": "Beijing Tiantan Hospital",
"gosset_sponsors": [
"Beijing Tiantan Hospital"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"glioblastoma (GBM)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 30,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05474378",
"title": "Phase I Clinical Trial of Locoregionally (LR) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Adults With Recurrent Glioblastoma Multiforme (GBM)",
"drugs": [
"B7H3-CART"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2022-07-12",
"start_year": 2022,
"sponsor": "Stanford University",
"gosset_sponsors": [
"Stanford University"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"glioblastoma multiforme (GBM)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 39,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06500819",
"title": "Phase I Clinical Trial of Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Children and Young Adults With Relapsed or Refractory Solid Tumor Expressing B7-H3 Target",
"drugs": [
"B7H3-CART"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-07-11",
"start_year": 2024,
"sponsor": "Stanford University",
"gosset_sponsors": [
"Stanford University"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"neuroblastoma",
"sarcoma",
"osteosarcoma (OS)",
"Ewing sarcoma",
"Wilms' tumor"
],
"disease_groups": [
"Neuroblastoma",
"Sarcomas"
],
"enrollment": 41,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06646627",
"title": "Phase I Clinical Trial of Autologous B7-H3 Chimeric Receptor (CAR) T Cells in Adults With Recurrent, Platinum Resistant Ovarian Tumors",
"drugs": [
"B7H3-CART"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-11-11",
"start_year": 2024,
"sponsor": "Stanford University",
"gosset_sponsors": [
"Stanford University"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"ovarian cancer"
],
"disease_groups": [
"Ovarian cancer"
],
"enrollment": 48,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06221553",
"title": "Safety and Efficacy of Intraventricular Infusion of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell in Diffuse Intrinsic Pontine Glioma",
"drugs": [
"B7H3-IL7Ra CAR-T"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-03-01",
"start_year": 2024,
"sponsor": "Chulalongkorn University",
"gosset_sponsors": [
"Chulalongkorn University"
],
"sponsor_class": "OTHER",
"countries": [
"Thailand"
],
"diseases": [
"diffuse intrinsic pontine glioma (DIPG)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 9,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06612645",
"title": "Safety and Efficacy of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD03) in Relapse and Refractory Pediatric Solid Tumors",
"drugs": [
"B7H3-IL7Ra CAR-T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-04-01",
"start_year": 2025,
"sponsor": "Chulalongkorn University",
"gosset_sponsors": [
"Chulalongkorn University"
],
"sponsor_class": "OTHER",
"countries": [
"Thailand"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 9,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT04185038",
"title": "Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors",
"drugs": [
"BCB-276"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2019-12-11",
"start_year": 2019,
"sponsor": "Seattle Children's Hospital",
"gosset_sponsors": [
"Seattle Children's"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"diffuse intrinsic pontine glioma (DIPG)",
"diffuse midline glioma (DMG)",
"central nervous system tumor"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 90,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT04483778",
"title": "Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
"drugs": [
"BCB-276"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Active, not recruiting",
"start": "2020-07-13",
"start_year": 2020,
"sponsor": "Seattle Children's Hospital",
"gosset_sponsors": [
"Seattle Children's"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"solid tumor",
"germ cell tumor (GCT)",
"retinoblastoma (Rb)",
"hepatoblastoma",
"Wilms' tumor",
"malignant rhabdoid tumor (MRT)",
"carcinoma",
"osteosarcoma (OS)",
"Ewing sarcoma",
"rhabdomyosarcoma (RMS)",
"synovial sarcoma (SS)",
"clear cell sarcoma (CCS)",
"malignant peripheral nerve sheath tumor (MPNST)",
"desmoplastic small round cell tumor (DSRCT)",
"soft tissue sarcoma (STS)",
"neuroblastoma",
"melanoma"
],
"disease_groups": [
"Solid tumours (basket)",
"Sarcomas",
"Neuroblastoma",
"Melanoma"
],
"enrollment": 68,
"combination": true,
"gosset_phase": 1
},
{
"nct_id": "NCT04385173",
"title": "A Pilot Study of Chimeric Antigen Receptor (CAR) T Cells Targeting B7-H3 Antigen in Treating Patients With Recurrent and Refractory Glioblastoma",
"drugs": [
"BCB-276"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Unknown",
"start": "2022-12-01",
"start_year": 2022,
"sponsor": "Second Affiliated Hospital, Zhejiang University, School of Medicine",
"gosset_sponsors": [
"Second Affiliated Hospital of Zhejiang University School of Medicine"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"glioblastoma (GBM)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 12,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT04077866",
"title": "B7-H3-Targeted Chimeric Antigen Receptor (CAR) T Cells in Treating Patients With Recurrent or Refractory Glioblastoma",
"drugs": [
"BCB-276"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Unknown",
"start": "2023-06-01",
"start_year": 2023,
"sponsor": "Second Affiliated Hospital, Zhejiang University, School of Medicine",
"gosset_sponsors": [
"Second Affiliated Hospital of Zhejiang University School of Medicine"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"glioblastoma (GBM)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 40,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT05143151",
"title": "Study on the Efficacy and Safety of CD276-targeted Chimeric Antigen Receptor T Cells (CD276 CAR-T) in Refractory Pancreatic Cancer",
"drugs": [
"CD276 autologous chimeric antigen receptor T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Unknown",
"start": "2021-07-01",
"start_year": 2021,
"sponsor": "Shenzhen University General Hospital",
"gosset_sponsors": [
"Shenzhen University General Hospital"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"pancreatic cancer (PC)"
],
"disease_groups": [
"Pancreatic cancer"
],
"enrollment": 10,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07052383",
"title": "A Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Efficacy of DIT309 Cell Injection in Subjects With Advanced Bone and Soft Tissue Sarcomas",
"drugs": [
"DIT309"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-11-06",
"start_year": 2025,
"sponsor": "Tcelltech Inc.",
"gosset_sponsors": [
"Tcelltech GmbH"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"osteosarcoma (OS)",
"soft tissue sarcoma (STS)"
],
"disease_groups": [
"Sarcomas"
],
"enrollment": 15,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07502287",
"title": "A Phase 1/Phase 2, Open-Label Study of BiomarkerInformed, Allogeneic Dual-Target GD2/B7-H3 (CD276) CAR-NK Cells in Children and Young Adults With Relapsed or Refractory Neuroblastoma",
"drugs": [
"EB-DTNB-NK"
],
"modality": "Cell therapy",
"modality_detail": "Natural Killer Cell Therapy",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-03-02",
"start_year": 2026,
"sponsor": "Beijing Biotech",
"gosset_sponsors": [
"Biotech Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"neuroblastoma",
"ganglioneuroblastoma (GNB)"
],
"disease_groups": [
"Neuroblastoma"
],
"enrollment": 36,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07500220",
"title": "A Phase 1/2, Open-Label, Dose-Escalation and Dose-Expansion Study of Allogeneic Dual-Target GPC3/B7-H3 (CD276) Chimeric Antigen Receptor Natural Killer Cells in Adults With Unresectable, Relapsed/Refractory, or Metastatic Hepatocellular Carcinoma",
"drugs": [
"EB-G3B7-NK"
],
"modality": "Cell therapy",
"modality_detail": "Natural Killer Cell Therapy",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-03-02",
"start_year": 2026,
"sponsor": "Beijing Biotech",
"gosset_sponsors": [
"Biotech Pharmaceutical"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"hepatocellular carcinoma (HCC)"
],
"disease_groups": [
"Liver cancer"
],
"enrollment": 30,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT05341492",
"title": "A Single-arm, Open, Exploratory Clinical Study Evaluating the Safety and Efficacy of EGFR/B7H3 CAR-T in Patients With EGFR/ B7H3-positive Advanced Solid Tumors (Lung and Triple-negative Breast Cancer)",
"drugs": [
"EGFR/B7-H3 CAR-T"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Early Phase 1",
"status": "Recruiting",
"start": "2022-05-01",
"start_year": 2022,
"sponsor": "Second Affiliated Hospital of Guangzhou Medical University",
"gosset_sponsors": [
"Second Affiliated Hospital of Guangzhou Medical University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"lung cancer",
"triple-negative breast cancer (TNBC)"
],
"disease_groups": [
"Lung cancer (unspecified)",
"Breast cancer"
],
"enrollment": 30,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT04842812",
"title": "Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors",
"drugs": [
"engineered TILs/CAR-TILs"
],
"modality": "Cell therapy",
"modality_detail": "CRISPR-based therapy",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2021-01-01",
"start_year": 2021,
"sponsor": "Second Affiliated Hospital of Guangzhou Medical University",
"gosset_sponsors": [
"Second Affiliated Hospital of Guangzhou Medical University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 40,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07193628",
"title": "An Open-label, First-in-human, Dose-escalation and Dose-expansion, Phase I Study of Fully Human B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy for Treatment of Recurrent or Refractory Glioblastoma",
"drugs": [
"EPC-003"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T cell therapy",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-09-26",
"start_year": 2025,
"sponsor": "Second Affiliated Hospital, Zhejiang University, School of Medicine",
"gosset_sponsors": [
"Second Affiliated Hospital of Zhejiang University School of Medicine"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"glioblastoma (GBM)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 14,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05211557",
"title": "A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of Fully Human B7H3 CAR-T in Treating Patients With Recurrent Malignant Ovarian Cancer",
"drugs": [
"fhB7H3.CAR-Ts"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Unknown",
"start": "2021-11-16",
"start_year": 2021,
"sponsor": "The Affiliated Hospital of Xuzhou Medical University",
"gosset_sponsors": [
"The Affiliated Hospital of Xuzhou Medical University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"ovarian cancer"
],
"disease_groups": [
"Ovarian cancer"
],
"enrollment": 15,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT05323201",
"title": "A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of B7H3 or HBsAg Targeting CAR-T in Treating Advanced Hepatocellular Carcinoma",
"drugs": [
"fhB7H3.CAR-Ts"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2022-02-10",
"start_year": 2022,
"sponsor": "The Affiliated Hospital of Xuzhou Medical University",
"gosset_sponsors": [
"The Affiliated Hospital of Xuzhou Medical University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"hepatocellular carcinoma (HCC)"
],
"disease_groups": [
"Liver cancer"
],
"enrollment": 15,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT04637503",
"title": "Multi-center Phase I/II Clinical Trial of 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma",
"drugs": [
"GD2 CAR-T cells + PSMA CAR-T cells + CD276 CAR-T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Not yet recruiting",
"start": "2026-12-31",
"start_year": 2026,
"sponsor": "Shenzhen Geno-Immune Medical Institute",
"gosset_sponsors": [
"Shenzhen Geno-Immune Medical Institute"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"neuroblastoma"
],
"disease_groups": [
"Neuroblastoma"
],
"enrollment": 100,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT06836505",
"title": "Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.",
"drugs": [
"GD2/B7H3 CAR-T"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2024-12-12",
"start_year": 2024,
"sponsor": "Sun Yat-Sen University Cancer Center",
"gosset_sponsors": [
"Sun Yat-sen University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"neuroblastoma",
"desmoplastic small round cell tumor (DSRCT)"
],
"disease_groups": [
"Neuroblastoma",
"Sarcomas"
],
"enrollment": 10,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07751380",
"title": "Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma",
"drugs": [
"hBRCA84D CAR-T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-07-23",
"start_year": 2025,
"sponsor": "University College, London",
"gosset_sponsors": [
"University College London"
],
"sponsor_class": "OTHER",
"countries": [
"United Kingdom"
],
"diseases": [
"rhabdomyosarcoma (RMS)",
"Ewing sarcoma",
"desmoplastic small round cell tumor (DSRCT)"
],
"disease_groups": [
"Sarcomas"
],
"enrollment": 12,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT04670068",
"title": "A Phase 1 Study of Autologous Activated T-cells Targeting the B7-H3 Antigen in Subjects With Recurrent Epithelial Ovarian Cancer",
"drugs": [
"iC9-CAR.B7-H3 T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Active, not recruiting",
"start": "2021-01-27",
"start_year": 2021,
"sponsor": "UNC Lineberger Comprehensive Cancer Center",
"gosset_sponsors": [
"UNC Lineberger Comprehensive Cancer Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"epithelial ovarian cancer (EOC)"
],
"disease_groups": [
"Ovarian cancer"
],
"enrollment": 4,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05366179",
"title": "Phase I Study of Intraventricular Infusion of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) in Subjects With Recurrent or Refractory Glioblastoma",
"drugs": [
"iC9-CAR.B7-H3 T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2022-09-02",
"start_year": 2022,
"sponsor": "UNC Lineberger Comprehensive Cancer Center",
"gosset_sponsors": [
"UNC Lineberger Comprehensive Cancer Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"glioblastoma multiforme (GBM)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 36,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06347068",
"title": "Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast Cancer",
"drugs": [
"iC9-CAR.B7-H3 T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-06-27",
"start_year": 2024,
"sponsor": "UNC Lineberger Comprehensive Cancer Center",
"gosset_sponsors": [
"UNC Lineberger Comprehensive Cancer Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"triple-negative breast cancer (TNBC)"
],
"disease_groups": [
"Breast cancer"
],
"enrollment": 42,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06158139",
"title": "A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)",
"drugs": [
"iC9-CAR.B7-H3 T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-07-18",
"start_year": 2024,
"sponsor": "UNC Lineberger Comprehensive Cancer Center",
"gosset_sponsors": [
"UNC Lineberger Comprehensive Cancer Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"pancreatic ductal adenocarcinoma (PDAC)"
],
"disease_groups": [
"Pancreatic cancer"
],
"enrollment": 27,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06305299",
"title": "Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects With Recurrent Platinum Resistant Epithelial Ovarian Cancer",
"drugs": [
"iC9-CAR.B7-H3 T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-07-29",
"start_year": 2024,
"sponsor": "UNC Lineberger Comprehensive Cancer Center",
"gosset_sponsors": [
"UNC Lineberger Comprehensive Cancer Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"epithelial ovarian cancer (EOC)"
],
"disease_groups": [
"Ovarian cancer"
],
"enrollment": 27,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06726564",
"title": "A Phase 1 Single Arm, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MT027 in Patients with Pleural Malignant Tumors",
"drugs": [
"MT027 CAR-T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-05-15",
"start_year": 2024,
"sponsor": "Suzhou Maximum Bio-tech Co., Ltd.",
"gosset_sponsors": [
"Suzhou Maximum Bio-tech"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"malignant pleural effusion (MPE)",
"pleural neoplasm",
"pleural mesothelioma",
"Pleural metastasis"
],
"disease_groups": [],
"enrollment": 18,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06742593",
"title": "A Single-arm, Dose-escalating Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic , and Efficacy of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors",
"drugs": [
"MT027 CAR-T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2025-01-01",
"start_year": 2025,
"sponsor": "Suzhou Maximum Bio-tech Co., Ltd.",
"gosset_sponsors": [
"Suzhou Maximum Bio-tech"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"glioma",
"Central Nervous System Metastasis (CNSM)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 12,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06737146",
"title": "A Single-arm, Dose-escalation Phase I Clinical Study on Evaluating the Tolerability, Pharmacokinetic Characteristics, Safety and Preliminary Efficacy of MT027 in Patients with Recurrent or Progressive High-grade Glioma",
"drugs": [
"MT027 CAR-T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Not yet recruiting",
"start": "2025-01-01",
"start_year": 2025,
"sponsor": "Suzhou Maximum Bio-tech Co., Ltd.",
"gosset_sponsors": [
"Suzhou Maximum Bio-tech"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"glioma"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 12,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06912152",
"title": "Phase I Dose-Escalation Study of MT027: Evaluating Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors",
"drugs": [
"MT027 CAR-T cells"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-05-12",
"start_year": 2025,
"sponsor": "Zhejiang University",
"gosset_sponsors": [
"Zhejiang University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"peritoneal neoplasms",
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 12,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06018363",
"title": "Allogeneic B7-H3 CAR-\u03b3\u03b4T Cell Therapy Recurrent/Progressive High Grade Glioma\uff08R/R HGG\uff09",
"drugs": [
"QH104"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2023-06-01",
"start_year": 2023,
"sponsor": "Dushu Lake Hospital Affiliated to Soochow University",
"gosset_sponsors": [
"Soochow University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"glioma"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 25,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT05768880",
"title": "Phase 1 Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors",
"drugs": [
"SC-CAR4BRAIN"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Active, not recruiting",
"start": "2023-05-05",
"start_year": 2023,
"sponsor": "Seattle Children's Hospital",
"gosset_sponsors": [
"Seattle Children's"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"diffuse intrinsic pontine glioma (DIPG)",
"diffuse midline glioma (DMG)",
"central nervous system tumor"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 72,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT04864821",
"title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor",
"drugs": [
"TAA06"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Early Phase 1",
"status": "Unknown",
"start": "2021-05-14",
"start_year": 2021,
"sponsor": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"PersonGen BioTherapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [],
"diseases": [
"osteosarcoma (OS)",
"neuroblastoma",
"gastric cancer (GC)",
"lung cancer"
],
"disease_groups": [
"Sarcomas",
"Neuroblastoma",
"Gastric / GEJ cancer",
"Lung cancer (unspecified)"
],
"enrollment": 24,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05190185",
"title": "A Clinical Trial of TAA06 Injection in Advanced Solid Tumors",
"drugs": [
"TAA06"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Unknown",
"start": "2021-06-01",
"start_year": 2021,
"sponsor": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"PersonGen BioTherapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"Malignant Melanoma (MM)",
"lung cancer",
"colorectal cancer (CRC)"
],
"disease_groups": [
"Melanoma",
"Lung cancer (unspecified)",
"Colorectal cancer"
],
"enrollment": 18,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05562024",
"title": "An Open-label, Dose-escalation, and Dose-expansion Phase I Trial of TAA06 Injection in Patients With Relapsed/Refractory Neuroblastoma",
"drugs": [
"TAA06"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2022-12-30",
"start_year": 2022,
"sponsor": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"PersonGen BioTherapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"neuroblastoma"
],
"disease_groups": [
"Neuroblastoma"
],
"enrollment": 24,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06951425",
"title": "A Phase l, Open-Label, Dose-escalation Study to Evaluate the Safety, Tolerability and Antitumor Activity of TH027 CAR-T Cells (TH-CART-027) in Subjects With Relapsed or Refractory Solid Tumors",
"drugs": [
"TH-CART-027"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Early Phase 1",
"status": "Not yet recruiting",
"start": "2025-06-01",
"start_year": 2025,
"sponsor": "Shanghai Tongji Hospital, Tongji University School of Medicine",
"gosset_sponsors": [
"Tongji Hospital"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"osteosarcoma (OS)",
"neuroblastoma",
"gastric cancer (GC)",
"lung cancer"
],
"disease_groups": [
"Sarcomas",
"Neuroblastoma",
"Gastric / GEJ cancer",
"Lung cancer (unspecified)"
],
"enrollment": 24,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07384390",
"title": "An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects With Recurrent or Progressive Grade 4 Glioma",
"drugs": [
"TH-CART-027"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Early Phase 1",
"status": "Not yet recruiting",
"start": "2026-01-30",
"start_year": 2026,
"sponsor": "Shanghai Tongji Hospital, Tongji University School of Medicine",
"gosset_sponsors": [
"Tongji Hospital"
],
"sponsor_class": "OTHER",
"countries": [],
"diseases": [
"glioma"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 21,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06482905",
"title": "A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Antitumor Activity of TX103 CAR-T Cell Injection (TX103) in Subjects With Recurrent or Progressive Grade 4 Glioma.",
"drugs": [
"tx-103"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2024-09-04",
"start_year": 2024,
"sponsor": "Tcelltech Inc.",
"gosset_sponsors": [
"Tcelltech GmbH"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China",
"United States"
],
"diseases": [
"glioma"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 52,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07231081",
"title": "An Open-label, Single-arm, Phase I Clinical Trial to Evaluate the Safety and Efficacy of TX103 CAR-T Cells in Participants With Advanced Solid Tumors",
"drugs": [
"tx-103"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2025-10-16",
"start_year": 2025,
"sponsor": "Tcelltech Inc.",
"gosset_sponsors": [
"Tcelltech GmbH"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 85,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05731219",
"title": "Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia",
"drugs": [
"UTAA06"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Unknown",
"start": "2022-09-26",
"start_year": 2022,
"sponsor": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"PersonGen BioTherapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"acute myeloid leukemia (AML)"
],
"disease_groups": [
"Leukaemias"
],
"enrollment": 18,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05722171",
"title": "Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute",
"drugs": [
"UTAA06"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Early Phase 1",
"status": "Unknown",
"start": "2022-12-27",
"start_year": 2022,
"sponsor": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
"gosset_sponsors": [
"PersonGen BioTherapeutics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"China"
],
"diseases": [
"acute myeloid leukemia (AML)"
],
"disease_groups": [
"Leukaemias"
],
"enrollment": 10,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06372236",
"title": "Phase I Clinical Study of UTAA06 Injection in Treatment of Patients With Advanced Malignant Solid Tumors",
"drugs": [
"UTAA06"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Phase 1",
"status": "Completed",
"start": "2023-12-05",
"start_year": 2023,
"sponsor": "Peking University",
"gosset_sponsors": [
"Peking University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"solid tumor"
],
"disease_groups": [
"Solid tumours (basket)"
],
"enrollment": 10,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT06825455",
"title": "Clinical Study of the Safety and Tolerability of B7H3 CAR-\u03b3\u03b4T Cell Injection in the Treatment of Advanced Solid Tumors",
"drugs": [
"UTAA06"
],
"modality": "Cell therapy",
"modality_detail": "CAR-T",
"phase": "Early Phase 1",
"status": "Not yet recruiting",
"start": "2025-03-01",
"start_year": 2025,
"sponsor": "Peking University",
"gosset_sponsors": [
"Peking University"
],
"sponsor_class": "OTHER",
"countries": [
"China"
],
"diseases": [
"solid tumor (advanced stage)",
"ovarian cancer",
"primary peritoneal cancer (PPC)"
],
"disease_groups": [
"Solid tumours (basket)",
"Ovarian cancer"
],
"enrollment": 18,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT01502917",
"title": "A Phase I Study of Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy",
"drugs": [
"124I-omburtamab"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1",
"status": "Completed",
"start": "2011-12",
"start_year": 2011,
"sponsor": "Y-mAbs Therapeutics",
"gosset_sponsors": [
"Y-mAbs Therapeutics, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"diffuse intrinsic pontine glioma (DIPG)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 50,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT01099644",
"title": "Phase I Study of Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum",
"drugs": [
"131I-omburtamab"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1",
"status": "Terminated",
"start": "2010-04",
"start_year": 2010,
"sponsor": "Y-mAbs Therapeutics",
"gosset_sponsors": [
"Y-mAbs Therapeutics, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"desmoplastic small round cell tumor (DSRCT)",
"primary peritoneal cancer (PPC)"
],
"disease_groups": [
"Sarcomas"
],
"enrollment": 54,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT05063357",
"title": "Safety of 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma Previously Treated With External Beam Radiation Therapy",
"drugs": [
"131I-omburtamab"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1",
"status": "Withdrawn",
"start": "2022-03",
"start_year": 2022,
"sponsor": "Y-mAbs Therapeutics",
"gosset_sponsors": [
"Y-mAbs Therapeutics, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [],
"diseases": [
"diffuse intrinsic pontine glioma (DIPG)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 0,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07189871",
"title": "A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors",
"drugs": [
"177Lu-BETABART"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1/2",
"status": "Recruiting",
"start": "2026-02-23",
"start_year": 2026,
"sponsor": "Radiopharm Theranostics, Ltd",
"gosset_sponsors": [
"Radiopharm Theranostics"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"castration-resistant prostate cancer (CRPC)",
"colorectal cancer (CRC)",
"non-small cell lung cancer (NSCLC)",
"ovarian cancer",
"Cervical Cancer (CC)",
"endometrial cancer (EC)",
"triple-negative breast cancer (TNBC)",
"small cell lung cancer (SCLC)",
"head and neck squamous cell carcinoma (HNSCC)",
"Esophageal Squamous Cell Carcinoma (ESCC)",
"sarcoma"
],
"disease_groups": [
"Prostate cancer",
"Colorectal cancer",
"Non-small cell lung cancer",
"Ovarian cancer",
"Breast cancer",
"Small cell lung cancer",
"Head & neck cancer",
"Oesophageal cancer",
"Sarcomas"
],
"enrollment": 61,
"combination": true,
"gosset_phase": 2
},
{
"nct_id": "NCT04167618",
"title": "A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-Omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory Medulloblastoma",
"drugs": [
"177Lu-DTPA-omburtamab"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1/2",
"status": "Terminated",
"start": "2021-09-30",
"start_year": 2021,
"sponsor": "Y-mAbs Therapeutics",
"gosset_sponsors": [
"Y-mAbs Therapeutics, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"Denmark",
"Netherlands",
"Spain",
"United Kingdom",
"United States"
],
"diseases": [
"medulloblastoma"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 2,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT04315246",
"title": "A Phase I/II Trial of Intracerebroventricular 177Lu DTPA Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors",
"drugs": [
"177Lu-DTPA-omburtamab"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1/2",
"status": "Withdrawn",
"start": "2022-08-31",
"start_year": 2022,
"sponsor": "Y-mAbs Therapeutics",
"gosset_sponsors": [
"Y-mAbs Therapeutics, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"United Kingdom",
"United States"
],
"diseases": [
"leptomeningeal metastasis (LM)"
],
"disease_groups": [],
"enrollment": 0,
"combination": false,
"gosset_phase": 2
},
{
"nct_id": "NCT07698899",
"title": "A Phase I Dose Escalation Trial of Compartmental Radioimmunotherapy (cRIT) Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory B7H3 Expressing Primary or Metastatic CNS Tumors",
"drugs": [
"177Lu-DTPA-omburtamab"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-07-02",
"start_year": 2026,
"sponsor": "Memorial Sloan Kettering Cancer Center",
"gosset_sponsors": [
"Memorial Sloan Kettering Cancer Center"
],
"sponsor_class": "OTHER",
"countries": [
"United States"
],
"diseases": [
"medulloblastoma",
"Central Nervous System Metastasis (CNSM)"
],
"disease_groups": [
"Brain & CNS tumours"
],
"enrollment": 18,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT07581184",
"title": "BActinium-1: A Phase 1b, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Intravenous Administration of B7-H3 Radiopharmaceutical ([225Ac]Ac-AKY-2519) in Metastatic Castration-Resistant Prostate Cancer",
"drugs": [
"AKY-2519"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1",
"status": "Recruiting",
"start": "2026-06-17",
"start_year": 2026,
"sponsor": "Aktis Oncology, Inc.",
"gosset_sponsors": [
"Aktis Oncology"
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"metastatic castration-resistant prostate cancer (mCRPC)"
],
"disease_groups": [
"Prostate cancer"
],
"enrollment": 138,
"combination": false,
"gosset_phase": 1
},
{
"nct_id": "NCT00089245",
"title": "Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms",
"drugs": [
"omburtamab"
],
"modality": "Radiopharmaceutical",
"modality_detail": "Radiopharmaceutical",
"phase": "Phase 1",
"status": "Terminated",
"start": "2004-02-05",
"start_year": 2004,
"sponsor": "Y-mAbs Therapeutics",
"gosset_sponsors": [
"Y-mAbs Therapeutics, Inc."
],
"sponsor_class": "INDUSTRY",
"countries": [
"United States"
],
"diseases": [
"central nervous system tumor",
"neuroblastoma",
"sarcoma",
"Carcinomatous Meningitis (CM)"
],
"disease_groups": [
"Brain & CNS tumours",
"Neuroblastoma",
"Sarcomas"
],
"enrollment": 177,
"combination": false,
"gosset_phase": 1
}
]